 Proactive Investors Australia |
Invion starts second phase trial for asthma treatment
Proactive Investors Australia Invion (ASX: IVX) has initiated the phase II “NIMA” clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative … |
View full post on asthma – Google News